Cell type characterization of Boost and Boost+ mDA neuron protocol in vitro and in grafted in unilateral 6-hydroxydopamine (OHDA)-induced Parkinsonian rats
This work presents an optimized mDA neuron differentiation strategy that builds on the clinical grade (“Boost”) protocol but includes the addition of FGF18 and IWP2 treatment (“Boost+”) at the mDA neurogenesis stage. Both protocols were characterized by single-nucleus RNA-seq and compared in terms of cell composition and authenticity to primary fetal and adult midbrain DA neurons.
This work presents an optimized mDA neuron differentiation strategy that builds on the clinical grade (“Boost”) protocol but includes the addition of FGF18 and IWP2 treatment (“Boost+”) at the mDA neurogenesis stage. Both protocols were characterized by single-nucleus RNA-seq and compared in terms of cell composition and authenticity to primary fetal and adult midbrain DA neurons.